Paris/July 13

From 2008.igem.org

(Difference between revisions)
Line 28: Line 28:
*'''Biobricks 2007'''
*'''Biobricks 2007'''
{| border="1"  
{| border="1"  
-
|align="center"|Strain
+
|align="center"|miniprep
 +
|align="center"|details
|align="center"|Transformation
|align="center"|Transformation
|-
|-
-
|MP1 (= J23100)
+
|align="center"|MP1
 +
|align="center"|J23100
|align="center"|ok
|align="center"|ok
|-
|-
-
|MP2 (= J23107)
+
|align="center"|MP2  
 +
|align="center"|J23107
|align="center"|ok
|align="center"|ok
|-
|-
-
|MP3 (= B0015)
+
|align="center"|MP3
 +
|align="center"|B0015
|align="center"|ok
|align="center"|ok
|-
|-
-
|MP5 (= JB0030)
+
|align="center"|MP5  
 +
|align="center"|JB0030
|align="center"|ok
|align="center"|ok
|-
|-
-
|MP6 (= E0422)
+
|align="center"|MP6
 +
|align="center"|E0422
|align="center"|ok
|align="center"|ok
|}
|}
Line 49: Line 55:
*'''Biobricks 2008'''
*'''Biobricks 2008'''
{| border="1"  
{| border="1"  
-
|align="center"|details
+
|align="center"|book
-
|align="center"|Strain
+
|align="center"|plasmid
|align="center"|Antibio
|align="center"|Antibio
|align="center"|Plate 2007
|align="center"|Plate 2007
 +
|align="center"|Results
|-
|-
|align="center"|2E_SP 1000
|align="center"|2E_SP 1000
Line 58: Line 65:
|align="center"|A
|align="center"|A
|align="center"|3O P1
|align="center"|3O P1
 +
|align="center"|No transformation
|-
|-
|align="center"|10F_SP 1001
|align="center"|10F_SP 1001
Line 63: Line 71:
|align="center"|A
|align="center"|A
|align="center"|19N P1
|align="center"|19N P1
 +
|align="center"|No transformation
|-
|-
|align="center"|4F_SP 1013
|align="center"|4F_SP 1013
Line 68: Line 77:
|align="center"|K
|align="center"|K
|align="center"|7K P2
|align="center"|7K P2
 +
|align="center"|No transformation
|-
|-
|align="center"|6H_SP 1001
|align="center"|6H_SP 1001
Line 73: Line 83:
|align="center"|A
|align="center"|A
|align="center"|6H P1
|align="center"|6H P1
 +
|align="center"|No transformation
|-
|-
|align="center"|6D_SP 1007
|align="center"|6D_SP 1007
Line 78: Line 89:
|align="center"|A
|align="center"|A
|align="center"| /
|align="center"| /
 +
|align="center"|No transformation
|-
|-
|align="center"|6B_SP 1001
|align="center"|6B_SP 1001
Line 83: Line 95:
|align="center"|A
|align="center"|A
|align="center"|24K P1
|align="center"|24K P1
 +
|align="center"|No transformation
|-
|-
|align="center"|10F_SP 1002
|align="center"|10F_SP 1002
Line 88: Line 101:
|align="center"|A
|align="center"|A
|align="center"|21G P3
|align="center"|21G P3
 +
|align="center"|No transformation
|-
|-
|align="center"|11F_SP 1002
|align="center"|11F_SP 1002
Line 93: Line 107:
|align="center"|A
|align="center"|A
|align="center"|23G P3
|align="center"|23G P3
 +
|align="center"|No transformation
|-
|-
|align="center"|4C_SP 1000
|align="center"|4C_SP 1000
Line 98: Line 113:
|align="center"|A
|align="center"|A
|align="center"|7O P1
|align="center"|7O P1
 +
|align="center"|No transformation
|-
|-
|align="center"|2G_SP 1000
|align="center"|2G_SP 1000
Line 103: Line 119:
|align="center"|A
|align="center"|A
|align="center"|5C P1
|align="center"|5C P1
 +
|align="center"|No transformation
|-
|-
|align="center"|1C_SP 1008
|align="center"|1C_SP 1008
Line 108: Line 125:
|align="center"|A
|align="center"|A
|align="center"|23E P1
|align="center"|23E P1
 +
|align="center"|No transformation
|-
|-
|align="center"|7G_SP 1013
|align="center"|7G_SP 1013
Line 113: Line 131:
|align="center"|K
|align="center"|K
|align="center"|15M P2
|align="center"|15M P2
 +
|align="center"|No transformation
|-
|-
|align="center"|7E_SP 1001
|align="center"|7E_SP 1001
Line 118: Line 137:
|align="center"|A
|align="center"|A
|align="center"|5H P1
|align="center"|5H P1
 +
|align="center"|No transformation
|-
|-
|align="center"|2F_SP 1016
|align="center"|2F_SP 1016
Line 123: Line 143:
|align="center"|K
|align="center"|K
|align="center"|7G P1
|align="center"|7G P1
 +
|align="center"|No transformation
|}
|}

Revision as of 08:22, 16 July 2008

 < Yesterday
-
Tomorrow > 

delete


Preparation of Competent Cells

  • Dilution 1/200e (1mL of the O/N culture on 200mL of LB)
  • Culture at 37°C until DO=0,57 (around 3h)
  • Sharing into 4 Falcon tubes of 50mL and cooling at 4°C during 40' in ice
  • Spin during 8', 2000rpm, 4°C
  • Resuspension of the cell's pellet in 20mL of cold CaCl2 (0,1M) during 30' in ice
  • Spin during 8', 2000rpm, 4°C
  • Resuspension of the cell's pellet in 1mL of cold CaCl2 (0,1M)
  • 1h of delay unexpected (problem with DNA lyophilized)
  • Transformation of the Biobricks with the "classical" protocol (--> heat shock at 42°C during 40")
  • Incubation O/N at 37°C of the transformed bacteria


Remark :

  • Biobricks 2007 : use of 3µl of the minipreps
  • Biobricks 2008 : use of the maximum recoverable volume of the minipreps


Liste of the transformation:

  • Biobricks 2007
miniprep details Transformation
MP1 J23100 ok
MP2 J23107 ok
MP3 B0015 ok
MP5 JB0030 ok
MP6 E0422 ok
  • Biobricks 2008
book plasmid Antibio Plate 2007 Results
2E_SP 1000 B0034 A 3O P1 No transformation
10F_SP 1001 R0079 A 19N P1 No transformation
4F_SP 1013 C0079 K 7K P2 No transformation
6H_SP 1001 C0179 A 6H P1 No transformation
6D_SP 1007 S03879 A / No transformation
6B_SP 1001 S03154 A 24K P1 No transformation
10F_SP 1002 J23101 A 21G P3 No transformation
11F_SP 1002 J23109 A 23G P3 No transformation
4C_SP 1000 R0040 A 7O P1 No transformation
2G_SP 1000 C0040 A 5C P1 No transformation
1C_SP 1008 PSB1A3 A 23E P1 No transformation
7G_SP 1013 E1010 K 15M P2 No transformation
7E_SP 1001 E0040 A 5H P1 No transformation
2F_SP 1016 E0030 K 7G P1 No transformation